Clinical Scorecard: Enhancing Grip Strength to Address Frailty in HIV Patients: Connecting Immune Fatigue to Bone Health Markers

At a Glance

Key Highlights

• Frailty in HIV patients is linked to immune exhaustion characterized by elevated PD-1 and TIGIT expression on CD4 T cells and a CX3CR1−CCR7− T-cell phenotype.
• Increased plasma osteoprotegerin (OPG) levels correlate with frailty and immune checkpoint markers, suggesting a connection between bone health and immune dysfunction.
• Senescent T-cell phenotypes defined by p16INK4a or CD57 were not associated with frailty, indicating heterogeneity in senescence markers and the need for precise immune profiling.

Guideline-Based Recommendations

Diagnosis

• Assess frailty using clinical criteria including weight loss, low physical activity, exhaustion, weakness, and slowness (Fried score).
• Evaluate handgrip strength as a physical performance measure to identify frailty.
• Consider immune profiling of T-cell phenotypes and checkpoint markers (PD-1, TIGIT) to understand immune exhaustion status.

Management

• Address frailty through multidisciplinary approaches targeting immune dysfunction and bone health.
• Explore therapeutic interventions targeting NF-κB signaling pathways and immune checkpoint modulation.
• Investigate potential use of immune modulators and senolytics to mitigate immune exhaustion and inflammation.

Monitoring & Follow-up

• Monitor inflammatory cytokines, especially IL-6, as part of the senescence-associated secretory phenotype.
• Track changes in naive and memory T-cell proportions and CD4/CD8 ratios to assess immune aging.
• Evaluate osteoprotegerin levels as a biomarker linking immune status and bone metabolism.

Risks

• Consider confounding factors such as depression, smoking, and statin use that may accelerate biological aging and influence frailty.
• Recognize that persistent immune activation may be exacerbated by coinfections and ART toxicity.
• Acknowledge the complexity and heterogeneity of senescent cell phenotypes complicating targeted interventions.

Patient & Prescribing Data

People living with HIV on ART exhibiting frailty symptoms

Current evidence supports targeting immune exhaustion and inflammation; however, specific pharmacologic treatments require further clinical validation.

Clinical Best Practices

• Use validated frailty assessment tools including physical performance tests like handgrip strength.
• Incorporate immune phenotyping to identify exhausted T-cell subsets linked to frailty.
• Adopt a multidisciplinary approach addressing immune, bone, and metabolic health to improve patient outcomes.
• Consider potential confounders and comorbidities when evaluating frailty and treatment responses.
• Support ongoing research into immune modulators and senolytic therapies as emerging options.

References

• Freeman et al., The Journal of Infectious Diseases
• Fried et al., Frailty Phenotype Definition
• Senescence-Associated Secretory Phenotype and IL-6
• Immune Checkpoint Markers PD-1 and TIGIT in HIV
• Osteoprotegerin Role in Bone and Immune Function